| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from continuing operations | -81,911,048 | -4,264,311 |
| Depreciation and amortization | 97,834 | 65,222 |
| Amortization of operating lease right-of-use assets | 413,081 | 271,099 |
| Non-cash write off of accounts payable and related accrued expenses | -676,678 | -676,678 |
| (gain) loss on derivative instruments | 74,366,000 | 0 |
| Vesting expense | 371,335 | 0 |
| Issuance of shares to non-employees | 200,000 | 66,667 |
| Loss on disposal of property and equipment | 0 | - |
| Accounts receivable | -8,145 | -11,197 |
| Inventories | -7,771 | -3,054 |
| Prepaid expense and other assets | 571,159 | 297,818 |
| Accounts payable | 1,883,017 | 511,791 |
| Accrued expenses and other | 363,660 | 371,361 |
| Contract liabilities | -77,500 | -75,000 |
| Operating lease liability | -408,955 | -267,216 |
| Other long-term liabilities | 0 | - |
| Net cash (used in) continuing operating activities | -5,934,497 | -4,280,632 |
| Purchase of property and equipment | 0 | 0 |
| Net cash (used in) continuing investing activities | 0 | 0 |
| Proceeds from issuance of common stock and warrants | 4,609,409 | 3,165,365 |
| Costs to issue common stock and warrants | 240,878 | 202,820 |
| Proceeds from issuance of financing note payable | 264,048 | 264,048 |
| Repayment of note payable | 76,674 | 0 |
| Net cash provided by continuing financing activities | 4,555,905 | 3,226,593 |
| Net cash provided by (used in) operating activities | 200,586 | 200,444 |
| Net cash provided by (used in) investing activities | 625,000 | 625,000 |
| Net cash provided by (used in) financing activities | 0 | 0 |
| Net cash provided by (used in) discontinued operations | 825,586 | 825,444 |
| Net (decrease) in cash | -553,006 | -228,595 |
Predictive Oncology Inc. (POAI)
Predictive Oncology Inc. (POAI)